Reuters - With the sudden failure of torcetrapib Pfizer Inc.'s most important experimental product financial analysts predict shares of the world's largest drugmaker could fall from 5 to 25 percent on Monday and that Pfizer will need to buy other products to fill the void.

¶ 12:21 AM